Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:28 PM ET 8-K
Investor Presentation Mid-America Apartments, L.P. MAA

Mid-America Apartments Investor Presentation

Mid-America Apartment Communities (MAA) filed a formal investor presentation deck to be used at the Nareit REITworld conference from November 17-19, 2026. The presentation provides strategic highlights and operational updates for the multifamily REIT. The filing was made under Item 7.01 of Form 8-K to comply with Regulation FD.

4:28 PM ET 8-K
Loan & Debt Guardant Health, Inc. GH

Guardant Health $550M Debt Financing with U.S. Bank Trust Company, National Association

Guardant Health completed a private offering of $550 million in 0% Convertible Senior Notes due 2032, which included the full exercise of the initial purchasers' option for an additional $50 million. The notes feature an initial conversion price of approximately $208.95 per share, representing a 35% premium over the November 11, 2026 closing price. Proceeds will be used to repurchase a portion of the company's existing 2027 convertible notes, fund capped call transactions, and for general corporate purposes.

Value
$550M
Counterparty
U.S. Bank Trust Company, National Association
Term
through May 2032
4:28 PM ET 8-K
Dividend Metlife Inc MET

Metlife Dividend

MetLife, Inc. declared quarterly cash dividends on its Series A, Series E, and Series F non-cumulative preferred stock. The dividends are payable on December 15, 2026, to shareholders of record as of November 30, 2026.

4:28 PM ET 8-K/A
Clinical Trial Data Cumberland Pharmaceuticals Inc CPIX

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.

Term
12 months
4:28 PM ET 8-K
Investor Presentation FB Financial Corp FBK

FB Financial Investor Presentation

FB Financial Corporation made available an investor presentation for use by management during various conferences in the fourth quarter of 2026. The presentation provides a strategic overview of the company's business segments, including its banking and mortgage operations.

4:28 PM ET 8-K
Loan & Debt Western Digital Corp WDC

Western Digital $1.5B Debt Financing with Bank of America, N.A.

Western Digital entered into a new $1.5 billion senior unsecured revolving credit facility maturing in 2031, replacing its existing 2022 loan agreement. The new facility features a $200 million sublimit for letters of credit and interest rates based on the company's credit ratings. The agreement includes a maximum leverage ratio covenant of 3.25 to 1.00, which can be temporarily increased following material acquisitions.

Value
$1.5B
Counterparty
Bank of America, N.A.
Term
5 years
4:28 PM ET 8-K/A
Business Update Cumberland Pharmaceuticals Inc CPIX

Cumberland Pharmaceuticals Business Update

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.

4:28 PM ET 8-K
Financial Results Aeon Biopharma, Inc. AEON

Aeon Biopharma Financial Results

AEON Biopharma reported Q3 2026 financial results and provided a regulatory update on its ABP-450 biosimilar program. The company received FDA Type 2b feedback clarifying its development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027.

Term
Q3 2026

“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®.”

Rob Bancroft, President and Chief Executive Officer

“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”

Rob Bancroft, President and Chief Executive Officer
4:28 PM ET 8-K
Leadership Change Stem, Inc. STEM

Stem Leadership Change

Stem, Inc. announced that Saul Laureles, Chief Legal Officer and Secretary, will leave the company effective November 24, 2026. The Board has appointed Jessica Palomino, the company's current Vice President and Senior Counsel – Operations, to succeed him as Chief Legal Officer and Secretary on the same date. Mr. Laureles will remain as a non-executive advisor through December 13, 2026, to ensure an orderly transition.

4:28 PM ET 8-K
Other 8-K Filing Dave Inc. DAVE

Dave Other 8-K Filing

Dave Inc. has filed applications with the OCC and FDIC to establish Dave Bank, N.A. as a full-service national bank and wholly-owned subsidiary. The company also intends to apply to the Federal Reserve to become a bank holding company, a move intended to allow Dave to offer deposit and credit products directly under federal supervision. In connection with the application, Anthony Sharett has been appointed as Chief Banking Officer and proposed President of the Bank.

Counterparty
Office of the Comptroller of the Currency (OCC)
4:28 PM ET 8-K
Leadership Change Jacobs Solutions Inc. J

Jacobs Solutions Leadership Change

Jacobs Solutions Inc. has appointed Richard D. Phillips to its Board of Directors, effective December 1, 2026, increasing the board size to 10 members. Phillips, currently the CEO of Kimball Electronics and a former McKinsey partner, will receive a $135,000 annual cash retainer and a pro-rated $200,000 annual RSU award. The appointment adds significant public company leadership and strategic advisory experience to the board as the company executes its long-term strategy.

Counterparty
Richard D. Phillips
Term
initial term through 2027 annual meeting
4:28 PM ET 8-K
Investor Presentation Sun Communities Inc SUI

Sun Communities Investor Presentation

Sun Communities, Inc. filed a formal investor presentation deck (Exhibit 99.1) to be used for investor meetings beginning November 16, 2026. The presentation provides strategic highlights and operational updates following the company's completed sale of its Park Holidays business unit.

4:28 PM ET 8-K
M&A Deal Aytu Biopharma, Inc AYTU

Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.

Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.

“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”

Josh Disbrow, Chief Executive Officer of Aytu

“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

Josh Disbrow, Chief Executive Officer of Aytu
4:28 PM ET 8-K
Financial Results Blue Dolphin Energy Co BDCO

Blue Dolphin Energy Financial Results

Blue Dolphin Energy Company reported Q3 2026 net income of $18.9 million, a significant turnaround from a net loss of $4.7 million in the prior year period. The company saw strong operational performance in its refinery segment, generating $23.9 million in refinery operations EBITDA for the quarter. Cash and cash equivalents improved to $40.8 million as of September 30, 2026, driven by $54.4 million in operating cash flow year-to-date.

Term
Q3 2026

“Blue Dolphin delivered another quarter of strong operational and financial performance by capitalizing on market opportunities. We remain focused on safe, reliable operations, margin capture, capital discipline, and value creation while enhancing refining capacity and capabilities.”

Jonathan P. Carroll, Chief Executive Officer of Blue Dolphin Energy Company
4:28 PM ET 8-K
Stock Buyback Neighborhood Intelligence, Inc. NXH

Neighborhood Intelligence Announces $25M Stock Buyback

Neighborhood Intelligence, Inc. announced that its Board of Directors has authorized a new share repurchase program to buy back up to $25 million of its outstanding common stock. The program allows for repurchases through open market or private transactions and has no fixed expiration date. This move signals management's commitment to returning capital to shareholders and confidence in the company's valuation.

Value
$25M
4:28 PM ET 8-K
Financial Results Firy Inc. FIRY

Firy Financial Results

Firy Inc. reported Q3 2026 revenue of $31.3 million, a 14% year-over-year increase, driven by 141% growth in its RZR segment. The company narrowed its net loss to $12.5 million and reached a debt-free status following the redemption of $49.7 million in senior secured notes in October. Management highlighted progress in collecting a $730 million judgment against Papaya Gaming and expects positive operating cash flow in 2027.

Term
Q3 2026

“We made substantial progress in Q3 2026, with strong execution across the organization driving accelerating momentum in our transition from turnaround to growth. Revenue grew 14% year over year, led by RZR, which grew 141% and for the first time made up the majority of quarterly revenue.”

Andrew Paradise, FIRY CEO

“Our third quarter results highlight the operating leverage in our business. Our net loss narrowed by $4.9 million year over year, and Adjusted EBITDA excluding litigation expense was a loss of $1.2 million, a $6.2 million improvement from a year ago.”

Alex Walsh, FIRY CFO
4:28 PM ET 8-K
Investor Presentation Diversified Healthcare Trust DHC

Diversified Healthcare Trust Investor Presentation

Diversified Healthcare Trust (DHC) filed a formal investor presentation for the NAREIT conference in November 2026. The presentation covers the company's 2026 guidance, senior housing operating portfolio (SHOP) optimization strategy, and strategic capital recycling plans. The filing is intended to provide updates on DHC's balance sheet improvements and asset management strategies to the investment community.

4:28 PM ET Form 4
Insider Buying FutureFuel Corp. FF

FutureFuel Insider Ronald J. Kruszewski Buys $284K of Stock

Ronald J. Kruszewski bought 100,000 shares of FutureFuel Corp. at $2.84 a share, worth $284K in total on Nov 12, 2026. Shares held after the trade: 110,000 (+1000.0%).

Value
$284K
Shares
100,000
Price
$2.84
Holding change
+1000.0%
Trade date
Nov 12, 2026
4:28 PM ET 8-K
Leadership Change e.l.f. Beauty, Inc. ELF

e.l.f. Beauty Leadership Change

e.l.f. Beauty appointed Amit Khetan, the company's current Chief Accounting Officer, to the additional role of principal accounting officer effective November 12, 2026. He succeeds Mandy Fields in this capacity, who will continue to serve as the company's Senior Vice President and Chief Financial Officer. Mr. Khetan will not receive any additional compensation in connection with this appointment.

4:28 PM ET 8-K
Financial Results Research Solutions, Inc. RSSS

Research Solutions Financial Results

Research Solutions reported its first quarter fiscal year 2027 results, highlighted by an 11.5% year-over-year increase in B2B Annual Recurring Revenue (ARR) to $16.5 million. While total revenue slightly decreased to $11.9 million due to lower transaction volume, gross margins improved by 300 basis points to 53.6% as the company continues its strategic shift toward higher-margin platform subscription revenue.

Term
Q1 2027

“Our continued investment in innovation is expanding how researchers discover, access, and engage with scientific literature. Recent launches of Article Galaxy and Scite integrations with ChatGPT, Claude, and Microsoft Copilot bring our capabilities directly into the AI-powered workflows researchers increasingly rely on, making it easier to find trusted evidence and access scholarly content.”

Roy W. Olivier, President and CEO

“Platform revenue accounted for 45% of total revenue this quarter, up from 42% a year ago, reflecting our continued transition toward a higher-margin, recurring revenue model. This evolution is strengthening profitability and operating cash flow, enabling us to reinvest in sales capacity and product innovation to accelerate long-term growth.”

Roy W. Olivier, President and CEO
4:28 PM ET Form 4
Insider Selling LifeStance Health Group, Inc. LFST

LifeStance Health Group Insider TPG Gp a LLC Sells $485M of Stock

TPG Gp a LLC sold 37,233,110 shares of LifeStance Health Group, Inc. at $13.02 a share, worth $485M in total on Nov 12, 2026. Shares held after the trade: 42,458,592 (-46.7%).

Value
$485M
Shares
37,233,110
Price
$13.02
Holding change
-46.7%
Trade date
Nov 12, 2026
4:28 PM ET Form 4
Insider Selling Merck & Co., Inc. MRK

Merck & Co EVP&Pres, Merck Animal Heallth Richard R. DeLuca Sells $8.61M of Stock

Richard R. DeLuca, EVP&Pres, Merck Animal Heallth, sold 58,185 shares of Merck & Co., Inc. at $148.01 a share, worth $8.61M in total on Nov 12, 2026. Shares held after the trade: 112,955 (-34.0%).

Value
$8.61M
Shares
58,185
Price
$148.01
Role
EVP&Pres, Merck Animal Heallth
Holding change
-34.0%
Trade date
Nov 12, 2026
4:28 PM ET Form 4
Insider Buying CV Sciences, Inc. CVSI

CV Sciences Insider Charlie E. Cheever III Buys $45.6K of Stock

Charlie E. Cheever III bought 4,557,721 shares of CV Sciences, Inc. at $0.01 a share, worth $45.6K in total between Nov 4, 2026 and Nov 9, 2026. Shares held after the trade: 31,706,432 (+6.7%).

Value
$45.6K
Shares
4,557,721
Average price
$0.0100
Holding change
+6.7%
Trade date
Nov 4, 2026 to Nov 9, 2026
4:26 PM ET Form 4
Insider Buying Senseonics Holdings, Inc. SENS

Senseonics Holdings Director Douglas A. Roeder Buys $176K of Stock

Douglas A. Roeder, Director, bought 17,041 shares of Senseonics Holdings, Inc. at $10.32 a share, worth $176K in total on Nov 13, 2026. Shares held after the trade: 189,712 (+9.9%).

Value
$176K
Shares
17,040
Price
$10.32
Role
Director
Holding change
+9.9%
Trade date
Nov 13, 2026
4:26 PM ET 10-K
Financial Results Marinemax Inc HZO

Marinemax FY 2026 Results: Net Loss of $8.2M, Loss Narrows

MarineMax is pursuing a growth strategy focused on acquisitions, new retail locations, and digital channel expansion, while navigating risks related to manufacturer approvals and integration. The company faces significant international exposure, particularly regarding foreign currency fluctuations and geopolitical tensions involving suppliers in Italy, Poland, Taiwan, and China.

Key figure
Net loss $8.2M
4:26 PM ET Form 4
Insider Selling Icon PLC ICLR

Icon Insider Ciaran Murray Sells $2M of Stock

Ciaran Murray sold 10,000 shares of Icon PLC at $200.18 a share, worth $2M in total on Nov 12, 2026. Shares held after the trade: 7,000 (-58.8%).

Value
$2M
Shares
10,000
Price
$200.18
Holding change
-58.8%
Trade date
Nov 12, 2026
4:26 PM ET Form 4
Insider Selling Ligand Pharmaceuticals Inc LGND

Ligand Pharmaceuticals Insider Martine Zimmermann Sells $636K of Stock

Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals Inc at $318.17 a share, worth $636K in total on Nov 12, 2026. Shares held after the trade: 1,782 (-52.9%).

Value
$636K
Shares
2,000
Price
$318.17
Holding change
-52.9%
Trade date
Nov 12, 2026
4:10 PM ET 10-Q
Financial Results Reliability Inc RLBY

Reliability Q3 2026 Results: Net Loss of $92K, Loss Narrows

Reliability Inc. reported a net loss of $417,000 for the nine months ended September 30, 2026, compared to a $742,000 loss in the prior year period. A significant balance sheet change occurred in mid-2026 when the company acquired 253,292,210 treasury shares in a non-cash settlement of related-party notes receivable, resulting in a total shareholders' deficit of $200,000.

Key figure
Net loss $92K
4:10 PM ET 10-Q
Financial Results HealthLynked Corp HLYK

HealthLynked Q3 2026 Results: Net Loss of $889K, Loss Widens

HealthLynked Corp reported a significant decline in total revenue to $0.83 million for the nine months ended September 30, 2026, compared to $1.76 million in the prior year. The company's net loss widened to $3.33 million, driven largely by a $2.43 million loss on the change in fair value of debt, despite a reduction in total operating expenses.

Key figure
Net loss $889K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.